Active gastrointestinal disease or other malabsorption syndromes

Gastrointestinal disorder(s) which, in the opinion of the Qualified/Principal Investigator, would significantly impede the absorption of an oral agent (e.g. intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection).

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Presence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of pazopanib

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128 (TAK-228)

Patients must not have malabsorption, swallowing difficulty, or other conditions that would interfere with the ingestion or absorption of dabrafenib or trametinib

Patients must not have had any clinically-significant GI bleeding within 6 months prior to registration and patients must not have a GI disorder which (at the discretion of the investigator) bears a high risk of perforation or fistula; examples of this include (but are not limited to) Crohn’s disease or tumor with transmural extension through the gastrointestinal lining

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Patients with known manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128 (TAK-228) are INELIGIBLE

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drugs including difficulty swallowing

Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of the study drug are not eligible

Known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease

Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib

Participants unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Gastrointestinal disease known to interfere with absorption

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

History of malabsorption or other condition that would interfere with absorption of study drugs

Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.

Gastrointestinal malabsorption, or any other condition that in the opinion of the investigator might affect the absorption of the study drug.

Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the Investigator, may interfere with oral drug absorption

Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of oral combination partners.

Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of oral combination partners

Pre-existing duodenal stent and/or any other gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128

Incidence of gastrointestinal disease that may significantly alter the absorption of ACY 241.

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drugs including difficulty swallowing

Must not have a gastrointestinal condition that would interfere with absorption

Patients who have a known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing are not eligible

Malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drugs

Unable to swallow tablets, patients with malabsorption syndrome, or any other GI disease or GI function that could interfere with absorption of study treatment

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Has gastrointestinal conditions that could affect the absorption of DS-3032b in the opinion of the Investigator.

Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastro intestinal function or GI disease

Any dysphagia, odynophagia, esophageal dysmotility or stricture, known GI malabsorption syndrome, or intractable diarrhea that may significantly alter the absorption of any of the components of SM-88, e.g., cirrhosis.

Gastrointestinal (GI) condition which could impair absorption of study medication or inability to ingest study medication

Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption of rucaparib

Active gastrointestinal (GI) conditions and uncontrolled irritable bowel disease or pre-existing GI disorders that may interfere with proper absorption of the study drug

Malabsorption condition that would alter the absorption of orally administered medications

Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of venetoclax

Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus

Known disorder affecting gastrointestinal absorption

Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn’s disease, ulcerative colitis, chronic diarrhea, malabsorption)

Presence of conditions that will interfere significantly with the absorption of drugs

A condition that would interfere with enteric absorption

Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing.

Gastrointestinal disorder(s) which, in the opinion of the Principal Investigator, would significantly impede the absorption of an oral agent (e.g. active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection).

Any gastrointestinal or metabolic condition that could interfere with absorption of oral medication

Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib

Manifestations of malabsorption due to prior gastrointestinal surgery, gastrointestinal disease, or an unknown reason that may alter the absorption of TAK-228. Patients with enteric stomata are also excluded.

Has malabsorption due to prior gastrointestinal (GI) surgery or GI disease

Gastrointestinal (GI) condition that could interfere with the swallowing or absorption of defactinib.

Gastrointestinal disease

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

GI condition that might limit absorption of oral agents

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or lenalidomide, including difficulty swallowing

Incidence of gastrointestinal disease that may significantly alter the absorption of ACY 241.

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing; patients with known GI involvement with mantle cell lymphoma who have no clinical evidence of active disease at the time of enrollment are eligible

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Gastrointestinal condition that could interfere with the swallowing or absorption of study medication

Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn’s disease, ulcerative colitis, chronic diarrhea, malabsorption)

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn’s disease, ulcerative colitis, chronic diarrhea, malabsorption)

Chronic gastrointestinal illness

Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption.

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing

Known history of difficulty swallowing, malabsorption or other conditions that may reduce absorption of the product.

Presence of gastrointestinal disease that would significantly affect compound absorption.

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Any known gastrointestinal disorder determined by the investigator that interferes with the absorption of rucaparib

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Gastrointestinal (GI) disorder that negatively affects absorption

Known dysphagia, short-gut syndrome, gastroparesis, or other condition(s) that limits the ingestion or gastrointestinal absorption of drugs administered orally

Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of study drugs, including difficulty swallowing tables

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drug, including difficulty swallowing. Gastroesophageal reflux under treatment with proton pump inhibitor or histamine H2 antagonist is allowed

Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.

Subjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of the study medication.

Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption (e.g. malabsorption syndrome, history of biliary tract disease), including refractory nausea or vomiting, or chronic GI disease which may affect absorption or tolerance to oral medications

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK-228. In addition, patients with enteric stomata are also excluded.

Presence of a gastrointestinal condition that may affect drug absorption

Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib

History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug

Difficulty swallowing, malabsorption, known active partial or complete bowel obstruction, or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of capecitabine

COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agent

COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agent

COHORT 3: ENDOMETRIAL CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agent

Malabsorption condition that would alter the absorption of orally administered medications

Dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of orally administered drugs

Gastrointestinal disorder or procedure which is expected to interfere significantly with absorption of study treatment.

Impairment of gastro intestinal (GI) function or GI disease.

Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of X-396.

Clinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomy

Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug

Gastrointestinal disorder affecting absorption (e.g., gastrectomy)

History of malabsorption or other condition that would interfere with absorption of cobimetinib.

Patients with a history of gastrointestinal surgery or other procedure that might, in the opinion of the investigator(s), interfere with the absorption or swallowing of the study drugs

Patients with inflammatory bowel disease and/or gastrointestinal (GI) ulcers and/or GI fistulas are eligible but only at the discretion of the study PI after personalized review of their medical history and proximity of SBRT targets to gastrointestinal mucosa

Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.

Current or recent (within 3 months) gastrointestinal disease that could impact the absorption (i.e., unmanageable diarrhea or malabsorption at the time of screening)

Subjects with significant gastrointestinal abnormalities that may affect absorption (e.g., gastric bypass, short gut syndrome).

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug.

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.

For oral cohorts: The subject has gastrointestinal disease or has had a procedure that is expected to interfere with the oral absorption or tolerance of the study drug (e.g., functionally relevant gastrointestinal obstruction, mucositis/stomatitis, or frequent vomiting).

Patients with known dysphagia, short-gut syndrome, or other conditions that would affect the ingestion or gastrointestinal absorption of drugs administered orally

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study treatment including difficulty swallowing

Has presence of a gastrointestinal condition that may affect drug absorption

Existing gastrointestinal disease affecting drug absorption such as celiac disease or Crohn's disease, or previous bowel resection which is considered to be clinically significant or could interfere with absorption.

Known gastrointestinal disease or gastrointestinal procedure that could interfere with the oral absorption or tolerance of study therapy, including difficulty swallowing.

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

For patients who are treated with oral 5-azacitidine, any gastrointestinal disorder that would interfere with the absorption, distribution, metabolism or excretion of the study drug

Participants with any clinically significant gastrointestinal abnormalities that may alter absorption

Gastrointestinal disorder affecting absorption.

Patients who are unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatment

Patients unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatment

Presence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of axitinib

Malabsorption syndrome or other gastrointestinal (GI) illness that could affect oral absorption of the study drug

Gastrointestinal (GI) function or disease that may significantly alter the absorption of the study drugs

Clinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomy

Unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

No gastrointestinal (GI) disorder that negatively affects absorption

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Gastrointestinal abnormalities including but not limited to:

Patients with any condition likely to interfere with absorption of the study medication

Manifestations of malabsorption due to prior gastrointestinal surgery, gastrointestinal disease, or for some other reason that may alter the absorption of MLN0128 or MLN1117. In addition, participants with enteric stomata are also excluded.

Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.

Has gastrointestinal abnormalities including:

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK-228. In addition, patients with enteric stomata are also excluded

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib, lenalidomide or dexamethasone including difficulty swallowing

Incidence of gastrointestinal disease that may significantly alter the absorption of lenalidomide

Any contraindication to oral agents or gastrointestinal disorder or procedure which expects to interfere significantly with absorption of protocol treatment.

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK-228; in addition, patients with enteric stomata are also excluded

Patient is unable to swallow oral medications or has impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption (including, but not limited to active inflammatory bowel disease, malabsorption syndrome); concomitant therapy with antacids and anti-emetics is permissible

Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn’s disease, ulcerative colitis, chronic diarrhea, malabsorption)

Major surgery to the upper GI tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption

History of gastrointestinal mal-absorption or gastric bypass surgery

Active gastrointestinal (GI) ulceration or hemorrhage

Clinically active existing gastrointestinal disease affecting drug absorption, such as celiac disease or Crohn’s disease

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of the study drugs including difficulty swallowing

Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or lenalidomide including difficulty swallowing

Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of this oral agent are not eligible

Subject has significant gastrointestinal abnormalities, including ulcerative colitis, chronic diarrhea associated with intestinal malabsorption, Crohn's disease, and/or prior surgical procedures affecting absorption or requirement for intravenous (IV) alimentation

No known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease

History of gastrointestinal (GI) bleed requiring transfusion

Gastrointestinal disorder affecting absorption

Patients unable to swallow tablets, patients with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study treatment

Known gastrointestinal disease or condition that affects the absorption of GT0918.

Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.

Active gastrointestinal conditions that are expected to impair absorption of orally administered medications

Have a history of gastric bypass surgery or severe malabsorption that may interfere with the absorption of the study agents

PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Gastrointestinal abnormalities causing impaired absorption requiring intravenous alimentation, prior surgical procedures affecting absorption including gastric resection, treatment for active peptic ulcer disease in the past 6 months, active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy, malabsorption syndromes

Significant gastrointestinal (GI) disorder(s) that could, in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 751 (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)

Significant gastrointestinal condition that could potentially impair the absorption or disposition of the drug

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK228; such as significant chronic diarrhea; in addition, patients with enteric stomata are also excluded

History of malabsorption or other condition that would interfere with absorption of vemurafenib

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128; in addition, patients with enteric stomata are also excluded

Clinically significant gastrointestinal disease, digestive dysfunction, or surgery that would compromise absorption of oral administration of medications

Gastrointestinal disorder affecting absorption

Patients with gastrointestinal impairment that would affect the absorption of enzalutamide or previous history of colitis

Patient has a history of gastrointestinal (GI) surgical procedures, non-surgical procedures or conditions that might interfere with the absorption or swallowing of the study drugs

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of TAK-228. In addition, subjects with enteric stomata are also excluded

CAPMATINIB EXCLUSION CRITERIA: Gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, short gut syndrome) or other malabsorption syndromes that would impact on drug absorption

CERITINIB EXCLUSION CRITERIA: Gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, short gut syndrome) or other malabsorption syndromes that would impact on drug absorption

REGORAFENIB EXCLUSION CRITERIA: Gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, short gut syndrome) or other malabsorption syndromes that would impact on drug absorption

ENTRECTINIB EXCLUSION CRITERIA: Gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, short gut syndrome) or other malabsorption syndromes that would impact on drug absorption

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing

Subjects with gastrointestinal conditions that could affect the absorption of DS-3032b in the opinion of the investigator

Inability to take medication orally, dysphagia or an active gastric ulcer resulting from previous surgery or a severe gastrointestinal disease,or any other condition that investigators believe may affect absorption of the investigational product;

Patients with any severe gastrointestinal or metabolic condition that could interfere with absorption of oral medications

Any gastrointestinal (GI) disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post major bowel resection

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

History of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the IMP, use of percutaneous endoscopic gastrostomy (PEG) tubes

History of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the IMP

Impairment of GI function or GI disease that may significantly alter the absorption of INC280

Gastrointestinal abnormality that would affect absorption of SGN-2FF

An active gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease, uncontrolled celiac)

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib

Known gastrointestinal disease or procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease

Patients who have a history of gastrointestinal surgery or other procedures that might in the opinion of the investigator, interfere with the absorption or swallowing of the study drug

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat

Significant gastrointestinal disorder(s), that could in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 092 (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)

A gastrointestinal disorder that may affect the absorption of study medication.

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of enzalutamide, including difficulty swallowing tablets

Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of lenvatinib.

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing; patients who have had cystectomy with conduit, neobladder, or pouch using a portion of their terminal ileum are allowed if, the patient is stable without clinically significant metabolic disturbances OR stoma- and/or anastomosis-related complications OR post-surgical gut abnormalities that would compromise drug absorption

Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of study drugs, including difficulty swallowing tablets

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Known gastro-intestinal disease or gastro-intestinal procedure that could interfere with the oral absorption or tolerance of MLN9708, including difficulty swallowing

The presence of poorly controlled gastrointestinal disorders that could affect the absorption of the afatinib (e.g. Crohn‘s disease, ulcerative colitis, chronic diarrhea, malabsorption)

Patient must be able to take oral medications; patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659 including difficulty swallowing tablets; diarrhea > Grade 1 despite supportive therapy.

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Gastrointestinal disorder or abnormality that would interfere with absorption of the study drug

Impaired gastrointestinal (GI) function or GI disease that may alter absorption of ceritinib or inability to swallow up to five ceritinib capsules daily

Gastrointestinal (GI) bleed within 30 days prior to registration on study

Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs

Any active gastrointestinal (GI) impairment which, in the opinion of the investigator, would impair or alter the absorption of ceritinib (e.g., ulcerative colitis, or Crohn’s disease)

Conditions leading to inadequate gastrointestinal tract absorption as determined by the treating physician and/or investigator

Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LCL161 as per physicians opinion

History of significant difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the tested product

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Active gastrointestinal (GI) hemorrhage within 2 weeks of study enrollment

Active gastrointestinal (GI) bleed within 2 weeks of study enrollment

Patients with known significant impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of quizartinib.

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral vemurafenib

Gastrointestinal disease that precludes absorption

Patients with impaired gastrointestinal absorption (severe diarrhea or short loop syndromes)

Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents

Inability or unwillingness to swallow INCB054828 or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of INCB054828.

Have gastrointestinal illness or disorder that could affect oral absorption of AP32788 (such as short gut syndrome, Crohn's disease, ulcerative colitis, or CTCAE grade 2 or greater diarrhea of any etiology at baseline).

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or idasanutlin including difficulty swallowing

Gastrointestinal abnormalities such as inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection; treatment for active peptic ulcer disease in the past 6 months; active gastrointestinal bleeding as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy; malabsorption syndromes

Gastrointestinal ailments that may alter the absorption of oral medications (i.e. bowel obstruction, short-gut syndrome)

Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Subjects with an acute gastrointestinal ulcer

Gastrointestinal diseases or conditions that could affect drug absorption or could alter the assessment of safety

Impairment of GI function

Gastrointestinal diseases or conditions that could affect drug absorption

Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months, inflammatory bowel disease)

Ability to take oral medications without medical history of malabsorption or other chronic gastrointestinal disease, or other conditions that may hamper compliance and/or absorption of the study agent

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.

Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Inability to swallow or retain oral medications or the presence of active GI disease or other conditions that will interfere significantly with the absorption, distribution, metabolism, or excretion of vorolanib

Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would reasonably impact drug absorption.

Pre-existing duodenal stent and/ or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib

Patients who have gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug are not eligible

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or ibrutinib, including difficulty swallowing

Gastrointestinal disorder affecting absorption

Current or recent (within 3 months of study treatment administration) gastrointestinal disease or conditions that could interfere with the swallowing or absorption of study medication or inability to tolerate oral medication

Incidence of gastrointestinal disease that may significantly alter the absorption of lenalidomide

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.

Clinical evidence of uncontrolled malabsorption and/or any other gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with the absorption of rucaparib

Patient must be able to take oral medications; patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug

Subjects with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis).

Subjects with gastrointestinal disorders likely to interfere with absorption of the study medication.

Patients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis), are ineligible

Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs

Gastrointestinal disorder affecting absorption

Subjects with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis)

Active inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic) or have a history of abdominal surgery or other medical condition that may, in the opinion of the treating physician, interfere with gastrointestinal motility or absorption

Patients with gastrointestinal disease, or those who have had a procedure that is expected to interfere with the oral absorption or tolerance of BAL101553 (e.g., functionally-relevant gastrointestinal obstruction, or frequent vomiting unresolved upon anti-emetic supportive care), are ineligible

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Gastrointestinal abnormalities including:\r\n* Inability to take oral medication;\r\n* Requirement for intravenous alimentation;\r\n* Prior surgical procedures affecting absorption including total gastric resection;\r\n* Treatment for active peptic ulcer disease in the past 6 months;\r\n* Active gastrointestinal bleeding as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy;\r\n* Malabsorption syndromes

History of diverticulitis, diverticulosis requiring antibiotic treatment or chronic ulcerative lower gastrointestinal (GI) disease such as Crohn’s disease, ulcerative colitis or other symptomatic lower GI conditions that might predispose to perforations

Gastrointestinal disorders that may interfere with absorption of oral agents, such as malabsorption syndromes; additionally, patients requiring drainage gastrostomy (e.g. percutaneous endoscopic gastrostomy [PEG] tube) and/or parenteral hydration and/or nutrition support are not eligible

Subjects with gastrointestinal abnormalities including inability to take oral\n             medication, malabsorption or other conditions like chronic inflammatory bowel disease\n             that may affect absorption.

Patient must not have prior gastrointestinal (GI) surgery or GI disease that might interfere with the absorption of TRC102

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-0610, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) grade > 1

Must be able to swallow capsules and have no evidence of gastrointestinal (GI) tract abnormality that would alter the absorption of oral medications

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the swallowing absorption of panobinostat and MLN9708

Any gastrointestinal disorder with diarrhea as a major symptom, such as Crohn’s, or pre-existing chronic diarrhea Common Terminology Criteria (CTC) grade >= 2 of any etiology; included are malabsorption disorders that in the opinion of the study physician may affect absorption of either afatinib or dasatinib

Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of sorafenib

Patients unable to swallow orally administered medication at treatment initiation and patients with gastrointestinal disorders likely to interfere with the absorption of the study medication

History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug

Patients with gastrointestinal (GI) tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s, ulcerative colitis)

Patients with known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of midostaurin; patients with gastric bypass surgery are excluded

Patient has a history of a gastrointestinal surgery or other procedures that might, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugs

Patients must not have significant gastrointestinal disorders with diarrhea as a major symptom (e.g. Crohn’s disease, malabsorption, etc)

Patients must not have known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of TAK-700, including difficulty swallowing oral medications per investigator’s clinical judgement

Patients with any condition that may increase the risk of gastrointestinal bleeding or gastrointestinal perforation, including:\r\n* Active peptic ulcer disease\r\n* Known gastrointestinal intraluminal metastatic lesions (gastrointestinal serosa metastatic lesions are permitted)\r\n* Inflammatory bowel disease (e.g., ulcerative colitis, Crohn’s disease) or other gastrointestinal conditions with increased risk of perforation\r\n* Patients with clinical symptoms or signs of gastrointestinal obstruction and patients who require parenteral hydration and/or nutrition

Patients with known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally

Patient must be able to swallow pills and have no significant impairment in gastrointestinal absorption including history of gastric bypass surgery

Subject has incidence of gastrointestinal disease that may significantly alter the absorption of LEN

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of GS-5829, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) Grade > 1

Clinically significant malabsorption syndrome or other gastrointestinal disease that would impact drug absorption

Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.

History of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the investigational product

Or any condition that might affect the absorption of orally taken medication

Gastrointestinal (GI) condition that interferes with drug absorption

Patients who have known gastrointestinal (GI) disease or GI procedures which could interfere with the oral absorption or tolerance of alisertib are not eligible; examples include (but are not limited to) partial gastrectomy, history of small intestine surgery, and celiac disease

Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.

Gastrointestinal disorder affecting absorption;

History of gastrointestinal disorders that may interfere with the absorption of study drug (including gastric bypass surgery)

Have malabsorption syndrome or other gastrointestinal (GI) illness or condition.

Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection and small intestinal resection).

Gastrointestinal tumors, tumors that have originated or metastasized to the liver, or other tumors known to interfere with the absorption, distribution, metabolism, or excretion of drugs.

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-0610, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >1.

History of a gastrointestinal condition that in the opinion of the Investigator may affect oral drug absorption.

History of gastrointestinal condition that may affect drug absorption.

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of GS-5829, including any unresolved nausea, vomiting, or diarrhea that is Common Terminology Criteria for Adverse Events (CTCAE) Grade > 1

known gastrointestinal disease or condition which may affect the absorption of ASN003;

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of everolimus, MLN0128, or MLN1117. In addition, participants with enteric stomata are excluded.

Known gastrointestinal (GI) disease or procedure that could interfere with the GI absorption or tolerance of bicalutamide, including difficulty swallowing oral medications.

Known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery with significant removal of the small intestine, and celiac disease

Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug

Patients with known severe impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of sorafenib

Any gastrointestinal (GI) disorder or liver disease

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing

Any current or recent (within 3 months) gastrointestinal disease that could potentially impact the ability to swallow and/or absorb study drug (i.e., gastrointestinal surgery, malabsorption syndrome)

History of diverticulitis, rectal bleeding or other lower gastrointestinal (GI) diseases predisposing to GI complications after radiation (will be determined by radiation oncologist)

Pre-existing duodental stent and/or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of study drug.

Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib in the opinion of the investigator

Known gastrointestinal condition that would interfere with swallowing or the oral absorption or tolerance of CUDC-907.

Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract.

Patients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis)

Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drug

Impairment of gastrointestinal (GI) function

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat

Impairment of GI function or GI disease that may significantly alter capecitabine drug absorption

Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug

Active gastrointestinal conditions that are expected to impair absorption of orally administered medications

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.

Subject has a gastrointestinal disorder affecting absorption.

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib (ixazomib citrate) including difficulty swallowing

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Any gastrointestinal (GI) or metabolic condition that could interfere with absorption of oral medication such as ongoing grade 3 or higher diarrhea, constipation, nausea, or vomiting

Subjects who had major surgery to the upper gastrointestinal tract, or who have a history of inflammatory bowel disease, malabsorption syndrome, or other medical condition that may interfere with oral drug absorption.

Any gastrointestinal disorder expected to limit absorption of ibrutinib

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of ceritinib or LEE011

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug

Patients with gastrointestinal comorbidities that would affect intake or absorption of ponatinib

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug; patients who are unable to orally swallow the study medication

Known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease

Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown or other reason that may alter the absorption of MLN0128.

Gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 or pomalidomide including difficulty swallowing

Patients with a known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Gastrointestinal disease, surgery or malabsorption that could potentially impact the absorption of the study drug

Have malabsorption syndrome or other GI illness that could affect oral absorption of the study drug.

Patients with a history of gastrointestinal surgery or other procedure that might, in the opinion of the investigator(s), interfere with the absorption or swallowing of the study drugs

Subjects with known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.

Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.

Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months)

Patients with impairment of gastrointestinal function that may alter the absorption of BKM120

History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of oral study drug(s) within 3 months of enrollment

History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug

Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent

Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent

Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent

Clinically significant gastrointestinal disorders that may interfere with absorption of drug

Impairment of gastrointestinal function

Presence of GI fistula

Current disease or condition known to interfere with absorption, distribution, metabolism, or excretion of drugs, at the Investigator's discretion.

Gastrointestinal abnormalities including:\r\n* Inability to take oral medications\r\n* Requirement for intravenous alimentation\r\n* Prior surgical procedure affecting absorption including total gastric resection\r\n* Treatment for active peptic ulcer disease in the past 6 months\r\n* Active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy\r\n* Malabsorption syndrome

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat

Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents

Presence of active gastrointestinal (GI) disease or other condition that could affect gastrointestinal absorption (e.g. malabsorption syndrome) or predispose a subject to GI ulceration; subjects with prior Whipple procedure are eligible

Able to swallow and retain orally administered medication. NOTE: Subject should not have any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels. For example, subjects should have no more than 50% of the large intestine removed and no sign of malabsorption (i.e., diarrhea).NOTE: If clarification is needed as to whether a condition will significantly affect the absorption of study treatments, contact the GSK Medical Monitor.

Refractory gastrointestinal (GI) disease that would prevent absorption of oral agents

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.

Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LCL161

No gastrointestinal (GI) disorder that negatively affects absorption

History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug

Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents

History of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (for example, Crohn’s disease, ulcerative colitis); patients requiring feeding tubes are permitted

Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months)

Subjects with known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.

Impairment of gastrointestinal function

Patients must be able to retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels; patients who have feeding tubes can enroll in the study provided that the capsules do not need to be modified

Any known contraindications to sorafenib including allergic reaction, pill-swallowing difficulty, uncontrolled hypertension or history of cardiac disease, significant gastrointestinal (GI) bleed within 30 days, metastatic brain disease, renal failure requiring dialysis

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drug

Clinically significant gastrointestinal disorders that may interfere with absorption of drug.

Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib.

Any gastrointestinal disease that could hinder the absorption of enzalutamide

Any gastrointestinal disease that could hinder the absorption of enzalutamide

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of midostaurin

The patient is unable to swallow pills or diagnosed with a gastrointestinal disorder that are likely to interfere with the absorption of the study drug or with the patient’s ability to take regular oral medication

History of gastrointestinal disorder or prior extensive gastrointestinal surgery that may interfere with sufficient absorption of the study compounds.

Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents

Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of the study drugs

History of GI perforation within 12 months prior to registration or presence of active GI disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of the study drugs

Gastrointestinal condition which could impair absorption of study medication

Impairment of gastrointestinal function

Significant GI disorder(s) that could interfere with the absorption, metabolism, or excretion of ARQ 087 (e.g. Crohn's disease, ulcerative colitis, extensive gastric resection)

Patients with any of the following conditions or complications are NOT eligible for participation:\r\n* Uncontrolled hypertension\r\n* Known hypersensitivity to ergot derivatives\r\n* History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve (to be determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis)\r\n* History of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders\r\n* Gastrointestinal (GI) tract disease resulting in an inability to take oral medication\r\n* Malabsorption syndrome\r\n* Require intravenous (IV) alimentation\r\n* History of prior surgical procedures affecting absorption\r\n* Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)

No prior GI perforation, or GI obstruction or involvement of the bowel on imaging

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PANOBINOSTAT or RUXOLITINIB

Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs

No known gastrointestinal (GI) pathology that would interfere with drug bioavailability

Significant gastrointestinal disorders that may interfere with absorption of tosedostat.

Circumstances likely to interfere with absorption of orally administrated drugs.

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat

Patients with impairment of gastrointestinal function or disease

History of diverticulitis, rectal bleeding or other lower gastrointestinal (GI) diseases predisposing to GI complications after radiation (will be determined by radiation oncologist)

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Diarrhea ? Grade 2, impaired gastrointestinal absorption

Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK medical monitor for guidance to enrol the subject;

Gastrointestinal abnormalities including:\r\n* Inability to take oral medication\r\n* Requirement for intravenous alimentation\r\n* Prior surgical procedures affecting absorption including gastric resection\r\n* Treatment for active peptic ulcer disease in the past 6 months\r\n* Active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy\r\n* Malabsorption syndromes

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat

Gastrointestinal disease that would impact on drug absorption

Malabsorption syndrome, (prior surgical procedures affecting absorption), or inflammatory gastrointestinal (GI) disease (e.g., Crohn’s, ulcerative colitis) which in the opinion of the study coordinator is likely to limit normal absorption of the drug

Have malabsorption syndrome or other gastrointestinal illness that could affect absorption of ponatinib

Significant gastrointestinal disorder(s) that could, in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 087 (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)

Patients with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis), therefore could affect the absorption of AMG 232 at the discretion of treating physician

Gastrointestinal (GI) tract disease that causes an inability to take oral medication, malabsorption syndrome, or a requirement for IV alimentation; prior surgical procedures affecting absorption; or uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption of study medication including difficulty swallowing

Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of the study drug, such as the inability to take oral medication in tablet form

History of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (eg, Crohn’s disease, ulcerative colitis); patients requiring feeding tubes are permitted

Malabsorption due to prior gastrointestinal (GI) surgery, GI disease

Gastrointestinal disease that would impact on drug absorption

Presence of surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug

History of gastrointestinal disease

Gastrointestinal conditions that could affect drug absorption including post surgical states such as gastric bypass

Known gastrointestinal disease or condition that affects the absorption of ASN001, or difficulty swallowing large capsules.

Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption

Patients with poorly controlled bleeding from gastric antral vascular ectasia (GAVE) or other gastrointestinal (GI) sites

Gastrointestinal disease that may interfere with drug absorption.

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat

Significant active gastrointestinal disease that might impair absorption of study therapy;

Able to swallow and retain orally administered study treatment and does not have any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.

Gastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication.

Known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease

Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease) within last 3 months

Gastrointestinal (GI) condition that could interfere with the swallowing or absorption of study medication

Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Gastrointestinal disorders that may significantly interfere with absorption of study drug

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months).

History of malabsorption or other condition that would interfere with absorption of vemurafenib/cobimetinib

An upper gastrointestinal or other condition that would impair swallowing or absorption of oral medication

History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug as determined by the investigator

Impairment of gastrointestinal function or gastrointestinal disease that may alter the absorption of sunitinib.

Active gastrointestinal (GI) conditions that might predispose to drug intolerance or poor drug absorption

Gastrointestinal condition which could interfere with the swallowing or absorption of study drug.

Known gastrointestinal (GI) disease or GI procedure that is expected to interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing; as determined by the investigator

Patients who cannot take oral medication, require intravenous alimentation, had prior surgical procedures affecting gastrointestinal absorption, or have active peptic ulcer disease

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Major gastrointestinal (GI) disease as defined but not limited to the following: history of inflammatory bowel disease or other illness resulting in chronic diarrhea, known achlorhydria or history of GI surgery that could reduce the acidity of the stomach, acute pancreatitis or cholecystitis within 6 months prior to Baseline, or GI disease that may interfere with the absorption of orally-administered drugs.

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing

History of gastrointestinal condition that might interfere with drug absorption

Impairment of GI function or GI disease that could interfere with the absorption of selinexor, including obstructed GI tract and uncontrolled vomiting or diarrhea.

Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.

Clinically significant gastrointestinal abnormalities that may affect absorption of investigational products

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty

Persistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion of the Investigator may influence drug absorption

Impairment of gastrointestinal (GI) function or GI disease that might significantly alter the absorption of study drug

2. GI condition that could interfere with the swallowing or absorption of study drug.

Gastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication.

Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product.

History of active peptic ulcer disease or major upper gastrointestinal (GI) bleed < 12 months; history of GI bleeding from the colorectal cancer primary is not an exclusion criterion

Impaired GI function or GI disease

A history of malabsorption or other condition that would interfere with absorption of vemurafenib or cobimetinib.

Patients with gastrointestinal (GI) absorptive problems making it unlikely to absorb study medication or more likely to experience GI toxicities

RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat; for example severe inflammatory bowel disease

NON-PROGRESSED DIPG (STRATUM 2): Patients have impairment of GI function or GI disease that may significantly alter the absorption of panobinostat; for example severe inflammatory bowel disease

Impairment of GI function or GI disease that may significantly alter the absorption of ceritinib

Patient must not have prior gastrointestinal (GI) surgery or GI disease that might interfere with the absorption of terameprocol

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LBH589

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-0610, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >1

Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug.

Gastrointestinal disorder affecting absorption.

Presence of gastrointestinal disease or any other condition that could interfere significantly with the absorption of the study drug.

History of malabsorption or other condition that would interfere with enteral absorption

Gastrointestinal condition which could impair absorption of study medication

History of prior or currently active small or large intestine inflammation (such as Crohn's disease or ulcerative colitis). Any predisposition for gastrointestinal (GI) toxicity requires prior approval from the Medical Monitor.

Clinically significant gastrointestinal abnormality that would affect absorption of the drug

Patients with impaired gastrointestinal absorption (severe diarrhea or short loop syndromes)

Gastrointestinal Function

Impairment of GI function or GI disease that may significantly alter the absorption of panobinostat.

Gastrointestinal disease or disorder that could interfere with the swallowing, oral absorption, or tolerance of CUDC-907; this includes uncontrolled diarrhea (> 1 watery stool/day), major abdominal surgery, significant bowel obstruction and/or gastrointestinal diseases that could alter the assessment of pharmacokinetics or safety, including but not limited to: irritable bowel syndrome, ulcerative colitis, Crohn’s disease and hemorrhagic coloproctitis

Participants with gastrectomy or pre-existing gastrointestinal disorders that may interfere with the proper absorption of the drug(s), as per conclusion of the clinical Investigator

Inability to swallow oral study treatment or any gastrointestinal disease or condition that would preclude adequate absorption of study treatment

Subject has significant gastrointestinal abnormalities, including ulcerative colitis, chronic diarrhea associated with intestinal malabsorption, Crohn's disease, and/or prior surgical procedures affecting absorption or requirement for intravenous (IV) alimentation.

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral WNT974/LGX818

Any gastrointestinal (GI) or metabolic condition that could interfere with absorption of oral medication such as ongoing grade 3 or higher diarrhea, constipation, nausea, or vomiting

Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally

Patients with gastrointestinal (GI) tract disease, causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis)

Impaired GI function or GI disease that may interfere with absorption of AZD8835 or patients unable to take oral medication

Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea or other gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents

Recurrent nausea and/or vomiting within 14 days before the first dose of alisertib or known gastrointestinal (GI) abnormality or GI procedure that could interfere with or modify the oral absorption or tolerance of alisertib. Examples include, but are not limited to, disease-related bowel obstruction, pancreatic insufficiency, use of pancreatic enzymes, a gastric condition (such as severe reflux or active peptic ulcer disease) that requires chronic and uninterrupted use of proton pump inhibitors, partial gastrectomy, history of small intestine surgery, and celiac disease.

Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug

Gastrointestinal disorder(s) which, in the opinion of the Qualified/Principal Investigator, would significantly impede the absorption of an oral agent.

Gastrointestinal disorders or abnormalities that would interfere with absorption of study drug

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of fluconazole or itraconazole including difficulty swallowing capsules.

Patients unable to take oral drugs (e.g. lack of physical integrity of the upper gastrointestinal [GI] tract or known malabsorption syndromes)

Presence of active GI disease or other condition (e.g., small bowel or large bowel resection) that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK Medical Monitor.

Any gastrointestinal disorder with diarrhea as a major symptom, such as Crohn's, or pre- existing chronic diarrhea CTCAE Grade ? 2 of any etiology. Included are malabsorption disorders or surgical procedures that in the opinion of the investigator may affect absorption of study drug;

Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.

Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption

Known impairment of gastrointestinal function that would alter drug absorption.

The subject has difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the trial drug. Subjects requiring total parenteral nutrition are to be excluded.

Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Impairment of GI function or GI disease that could interfere with the absorption of AEB071 or everolimus.

History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.

Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents

Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of orteronel, including difficulty or inability to swallow tablets

Impairment of gastrointestinal function/disease that may significantly alter the absorption of everolimus.

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat

Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.

Significant gastrointestinal disorder(s), (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection) such that, in the opinion of the treating investigator, absorption of oral medications may be impaired.

Presence of any clinically significant gastrointestinal (GI) abnormality or other condition(s) that may alter absorption such as malabsorption syndrome or major resection of the stomach or substantial portion of the small intestine

Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption of drugs.

Patients with gastrointestinal disorders or abnormalities that would interfere with absorption of study treatment.

History of malabsorption or other condition that would interfere with enteral absorption

Inability to absorb abiraterone after oral administration (i.e., previous major gastrointestinal surgery or gastrointestinal disease resulting in malabsorption)

Patients with a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat

History of gastrointestinal (GI) hemorrhage

Known gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption, or tolerance of IXAZOMIB

Clinically significant gastrointestinal (GI) abnormalities that may increase the risk for GI bleeding.

Clinically significant GI abnormalities that may affect absorption of investigational product.

Incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide

Significant gastrointestinal disorder(s), in the opinion of the investigator, that may influence drug absorption

Impairment of gastro-intestinal (GI) function or GI disease that may significantly alter the absorption of LEE011 such as patients with a history of GI surgery which may result in intestinal blind loops and patients with clinically significant gastroparesis, unresolved nausea, vomiting, or diarrhea of CTCAE grade > 1

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat

gastrointestinal impairment or disease that may interfere with drug absorption

Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism or excretion of drugs.

Presence of GI disease, malignant tumors or other conditions known to interfere with ADME

Any gastrointestinal disorders which may interfere with the absorption of oseltamivir

Impairment of GI function or GI disease that may significantly alter the absorption of LBH589

Any gastrointestinal disorder expected to limit absorption of ibrutinib

Inability or unwillingness to swallow oral medication; manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption; in addition, patients with enteric stomata are also excluded

Presence of active gastrointestinal (GI) disease (including GI bleeding or ulceration) or other condition that could affect GI absorption) (e.g. malabsorption syndrome, history of biliary tract disease)

Patients must be able to swallow pills and have no significant impairment in gastrointestinal absorption

Ongoing gastrointestinal medical condition such as Crohn’s disease, inflammatory bowel disease, chronic diarrhea, or chronic constipation that could interfere with absorption of oral medication

Gastrointestinal conditions that may significantly affect the absorption of regorafenib

Gastrointestinal disorders that would interfere with drug absorption

History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agent

Evidence of >= grade 2 gastrointestinal toxicity (including, but not limited to: nausea, vomiting, anorexia, gastrointestinal pain)

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659.

Gastrointestinal disorder affecting absorption.

Gastrointestinal disorder affecting absorption.

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659 including difficulty swallowing tablets or diarrhea >Grade 1 despite supportive therapy.

Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus

Gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug

Active uncontrolled stage 3-4 acute gastrointestinal (GI) GVHD prior to administration of ibrutinib

Impaired gastrointestinal function (GI) or GI disease that may significantly alter the absorption of oral medications

PATIENT: Diagnosis of lung or gastrointestinal (GI) (colorectal, pancreas, liver) cancers

Previously unable to tolerate either supplement due to taste or gastrointestinal (GI) side effects.

No grade 3 or 4 gastrointestinal (GI) toxicity at time of initial screening

Gastrointestinal disorders in the opinion of the treating physician that would impair absorption

Impaired gastrointestinal absorption

History of clinically-significant gastrointestinal (GI) disease; GI perforation within 1 year; GI bleeding or acute pancreatitis within 3 months; or diverticulitis within 4 weeks of first study drug administration

History of malabsorption or other gastrointestinal (GI) disease that may significantly alter the absorption of LAM-002A

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of ranolazine

Medical contraindications to undergoing endoscopy or obstruction of the gastrointestinal (GI) tract that precludes passage of the endoscope

Personal history of any chronic gastrointestinal (GI) disorder (i.e., irritable bowel syndrome, colitis)

Gastrointestinal, or biliary disorders that could impair absorption, metabolism, or excretion of orally administered medications

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Patients with known gastrointestinal conditions that could potentially interfere with absorption of orally administered medications

Patients with any of the following conditions or complications are NOT eligible for participation:\r\n* Gastrointestinal (GI) tract disease resulting in an inability to take oral medication\r\n* Malabsorption syndrome\r\n* Require intravenous (IV) alimentation\r\n* History of prior surgical procedures affecting absorption\r\n* Uncontrolled inflammatory GI disease (e.g., Crohn’s, ulcerative colitis)

Individuals with any history of transfusion-dependent gastrointestinal bleeding, gastrointestinal perforation or gastrointestinal obstruction; if any of these events had been due to a malignancy of the GI tract and the malignancy has since been removed, the patient is eligible

Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-0610, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >1

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus

Patients with known manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of MLN0128 (TAK-228) are ineligible

Participants unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral Everolimus;

History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of orally administered hormonal agents

Active difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions (including pancreas deficiency requiring Creon therapy) that may hamper compliance and/or absorption of M3541

Active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.

History or current evidence of gastrointestinal malabsorption which, in the opinion of the investigator, may affect the extent of absorption of pritelivir.

Patients with a diverting ileostomy, with a history of inflammatory bowel disease, familial adenomatous polyposis (FAP), or active gastrointestinal (GI) symptoms (gastrointestinal bleed, diarrhea, severe abdominal pain, etc.)

History or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolism

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months)

Known gastrointestinal (GI) abnormality (including recurrent nausea or vomiting) or GI procedure that could interfere with or modify the oral absorption or tolerance of alisertib.

Currently active gastrointestinal (GI) disease, or prior surgery that may affect ability to absorb oral medications

Known gastrointestinal (GI) disease or prior GI procedure that could interfere with the oral absorption or tolerance of the TAK-580.

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659, including difficulty swallowing tablets or diarrhea greater than (>) Grade 1 despite supportive therapy.

Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659 including difficulty swallowing tablets; diarrhea >Grade 1 despite supportive therapy.

Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications.

Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption

Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of study drug.